Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients
about
Insights on common vaccinations in HIV-infection: efficacy and safetyA significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral loadVirological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis.Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent forLimited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapyFrench 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.High rates of virological suppression in a cohort of human immunodeficiency virus-positive adults receiving antiretroviral therapy in ethiopian health centers irrespective of concomitant tuberculosisHIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ARTPersistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settingsNovel codon insert in HIV type 1 clade B reverse transcriptase associated with low-level viremia during antiretroviral therapy.Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access.Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation.HIV-1 low copy viral sequencing-A prototype assay.Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.Editorial Commentary: Extending HIV drug resistance testing to low levels of plasma viremia.Expansion of Viral Load Testing and the Potential Impact on Human Immunodeficiency Virus Drug Resistance.First field evaluation of the optimized CE marked Abbott protocol for HIV RNA testing on dried blood spot in a routine clinical setting in Vietnam.
P2860
Q26770665-2DA874E7-97DD-480E-BBE3-AE851F6C3CF6Q28543626-83DF0E2A-DC7C-4547-9607-01732B4791D4Q33584656-496B3DA9-2263-4D09-8E70-D097D61DFD95Q33703537-3F0E5742-EDB7-4597-8E34-186A83EAC544Q33721466-B13BAE73-D680-44B0-9AF0-8BD89C8E4A88Q33775397-9113A13D-E181-4636-8261-95115A723344Q33798584-AC2D648F-CC3E-4352-BED7-34816C44F14AQ33880782-743AE4C9-BE96-46E7-B1AB-F06AD32A2D7CQ33934935-112FEDA2-48F7-4659-82E7-C42F79FF358FQ33963458-66E2DDE0-3E3D-4E75-B442-5CEE310625DBQ34289476-2EFA4ECC-7FC6-4E88-8CFE-8BAEAA49BC22Q34420782-BD0991D4-CF3B-49D9-861B-98A37D325409Q35071944-2C2CA3BD-5B4A-4D9E-AF34-1A90353EE65EQ35698144-789FAA60-8D04-4A44-9F55-991D9DAB2385Q35991216-ED6796C0-3DE6-4143-8BCB-49EAD331821DQ36246775-CF2849D2-BAAE-416C-850E-FCDCE7CDCDAEQ36364052-70B6A877-9283-40CA-8596-B25180381FC5Q37116750-49D79F00-0790-4A9B-8020-49CECDBAE67DQ37543319-397A1E29-105E-40A1-9804-3DFD4887796AQ37546182-FB367AAF-29E1-4415-B91A-FBD18D372AA0Q37668850-942FC269-F825-4CD1-9F65-36D477DE881DQ38383070-62F06EDD-214B-4C63-8CDE-110775A97235Q38418110-FEE06B91-451E-4CBF-87BC-691B13D9832AQ38709087-F0E3F07B-EE82-4AFE-B4B7-E958BDBE9EAAQ40111552-233822A5-A790-48CB-93C3-4EB0AE2B6162Q40278469-BF6F670D-B9FE-423F-8CE0-63083EA49F43Q41465991-20301838-7F98-4792-8255-E3DB50D89B75Q42243024-074520F4-7001-4D27-9B9F-2B29EF6E531AQ42276682-57CFC793-43FA-4394-9652-DAD1BD6248C7Q44864490-723AF1BC-81DC-4C9B-BE60-302DFBDCF6ABQ45326389-BDB1F6D3-855E-4FE3-926C-1AC865411554Q50099405-C5DD778E-8787-4051-A491-1FAFF4EEECD9
P2860
Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@ast
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@en
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@nl
type
label
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@ast
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@en
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@nl
prefLabel
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@ast
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@en
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@nl
P2093
P2860
P3181
P1433
P1476
Impact of low-level-viremia on ...... ntiretroviral treated-patients
@en
P2093
Constance Delaugerre
Dominique Mathez
Jean-Michel Molina
Julie Timsit
Pierre de Truchis
Rishma Amarsy
Samuel Ferret
Sébastien Gallien
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0036673
P407
P577
2012-01-01T00:00:00Z